Abstract Library

#4427 Surufatinib combined with hepatic artery infusion chemotherapy (HAIC) as second-line and maintenance therapy for neuroendocrine carcinoma with liver metastases: A single-arm, open-label, single-centre phase II clinical study (SuHaNec)

Introduction: Neuroendocrine carcinoma (NEC) is rare and highly aggressive, and liver metastasis leads to worse outcomes for patients (pts) with limited treatment options and poor prognosis. Surufatinib (SUR) exhibited promising antitumour activity in neuroendocrine neoplasms.

Conference:

Presenting Author:

Authors: Wang Y, Wang J, Yang D, Yao W, Zhang N,

Keywords: neuroendocrine carcinoma, surufatinib, hepatic artery infusion chemotherapy, later-line treatment,

#3940 Heterogenous uptake of 68Ga-DOTATATE and 18F-FDG in patients with initially diagnosed neuroendocrine tumors: Which patients are suitable for dual-tracer PET imaging?

Introduction: PET scans using FDG and DOTATATE have both been used to study neuroendocrine tumors (NETs).

Conference:

Presenting Author: Yi Z

Authors: Yi Z, Hui W, Ming Gang S, Rong T,

Keywords: 668Ga-DOTATATE, 18F-FDG, neuroendocrine tumor, prognosis,

#3325 Endoscopic ultrasound elastography in diagnostics of gastroenteropancreatic neuroendocrine tumors

Introduction: An important role of the endoscopic ultrasound (EUS) was found in the diagnostics of neuroendocrine tumors of the gastrointestinal tract (GEP NETs). In recent years, other modalities have been developed which, in combination with the EUS, improve diagnostics and allow prediction of the tumor's biological behaviour. Such methods include elastography (EG). EG is based on demonstrating the difference in tissue stiffness between tumor and reference area.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Uhrík P, Smolár M, Huťka Z, Nosakova L, Ďuríček P,

Keywords: endosonography, elastography, neuroendocrine tumor,

#3033 First-in-Korea Clinical Trial of Lu-177-DOTATATE in Patients with Inoperable, Progressive Somatostatin Receptor-Positive, Metastatic or Locally Advanced Neuroendocrine Tumor (SNU-KB-01)

Introduction: Peptide receptor radionuclide therapy (PRRT) based on Lu-177 DOTATATE is currently used worldwide as a treatment option for neuroendocrine tumor patients. But until now, no PRRT has been approved by the Korea Food and Drug Administration (KFDA). Thus, neuroendocrine tumor patients in Korea have severely limited access to the treatment. To provide treatment opportunities, we have planned a First-in-Korea phase I clinical trial of SNU-KB-01, no-carrier added Lu-177 labeled DOTATATE.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Suh M, Cheon G, Lee D,

Keywords: PRRT, clinical trial, Neuroendocrine tumor, Lu-177-DOTATATE,

#2839 The Second Revision of Clinical Practice Guidelines in GEP-NEN in Japan

Introduction: Japanese Neuroendocrine Tumor Society (JNETS) has published the first edition of clinical practice guidelines in gastroenteropancreatic neuroendocrine neoplasm (GEP-NEN) in 2015. Then, according to an update on the diagnosis and management of GEP-NEN in Japan. Revised clinical practice guidelines, the second edition, has just published in 2019.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Ito T, Masui T, Komoto I,

Keywords: GEP-NEN, Guideline, Japan,